Objective response rate was 12.5% (3 of 24 patients) by RANO 2.0, compared with 8.3% (2 of 24 patients) in the August topline results Median overall survival was 26.1 months from the start of NEO100 treatment at recurrence, as previously reported CALABASAS, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today reported updated interim results from the Phase 2a portion of NEO100-01, an open-label study of intranasal NEO100 in patients with recurrent or progressive Grade III or Grade IV IDH1-mutant glioma.